Fennec Pharmaceuticals Launches Pedmark (sodium thiosulfate injection) in the US
Shots:
- The company reported the commercial availability of Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients aged ≥1mos. with localized, non-metastatic solid tumors
- The company launched the comprehensive single source program i.e., Fennec HEARS to connect Pedmark patients with financial and product access support incl. access to care coordinators, and prescription drug support
- The MAA for sodium thiosulfate is currently under EMA’s review. Pedmark marks the first FDA-approved therapy to reduce the risk of Cisplatin-Induced hearing loss in pediatric patients & has Priority Review
Ref: Globenewswire | Image: Fennec
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
